Artivion (AORT)
(Delayed Data from NYSE)
$23.60 USD
-0.25 (-1.05%)
Updated May 31, 2024 04:00 PM ET
After-Market: $23.59 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AORT 23.60 -0.25(-1.05%)
Will AORT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AORT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AORT
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
Artivion (AORT) Tops Q1 Earnings and Revenue Estimates
AORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?
Are Medical Stocks Lagging Artivion (AORT) This Year?
Other News for AORT
Artivion price target raised by $5 at Needham, here's why
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
NanoViricides, TC BioPharm, Holdco Nuvo among healthcare movers
Artivion rises 15.7%
Artivion rises 16.7%